Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          

TRIA11

TRIA11

Request for Collaboration
Overview
TRIA11 is a biosimilar indicated for osteoporosis. The current global sales of the original product reaches to $1.7 billion. An injection pen is also developed to enhance the convenience of use.  TRIA11 is planned to launch in EU first, and TSH Biopharm has consulted EMA for the development plan. TRIA11 is expected to move into clinical stage by the end of 2019.
People who like this also like
  • Isoniazid without liver toxicityIsoniazid without liver toxicity
  • Homogeneous antibody drugs (CHO-H01, H02, H03)Homogeneous antibody drugs (CHO-H01, H02, H03)
  • TLC178TLC178
  • TLC599TLC599
  • SNP-830/SNP-840SNP-830/SNP-840
  • Carrier screening for fragile X syndromeCarrier screening for fragile X syndrome
  • LT1001LT1001
  • SNP-810 (OTC)SNP-810 (OTC)
  • RNTA06RNTA06
  • Preimplantation Genetic DiagnosisPreimplantation Genetic Diagnosis